436 related articles for article (PubMed ID: 30334460)
41. Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases.
Rack K; Vidrequin S; Dargent JL
J Clin Pathol; 2016 Jan; 69(1):82-6. PubMed ID: 26338801
[TBL] [Abstract][Full Text] [Related]
42. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system.
Durie BG
Eur J Cancer; 2006 Jul; 42(11):1539-43. PubMed ID: 16777405
[TBL] [Abstract][Full Text] [Related]
43. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma".
Hillengass J; Landgren O
Leuk Lymphoma; 2013 Jul; 54(7):1355-63. PubMed ID: 23289361
[TBL] [Abstract][Full Text] [Related]
44. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies.
Bisht K; Walker B; Kumar SK; Spicka I; Moreau P; Martin T; Costa LJ; Richter J; Fukao T; Macé S; van de Velde H
Expert Rev Hematol; 2021 Dec; 14(12):1099-1114. PubMed ID: 34551651
[TBL] [Abstract][Full Text] [Related]
45. Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma.
Wang ZL; Liu Y; Zhou YL; Li JL; Sun QY; Wu LX; Wen L; Lai YY; Liu YR; Chang YJ; Shi HX; Liu KY; Huang XJ; Lu J; Ruan GR
Eur J Haematol; 2020 Aug; 105(2):185-195. PubMed ID: 32282962
[TBL] [Abstract][Full Text] [Related]
46. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F; Kastritis E; Zomas A; Terpos E; Katodritou E; Symeonidis A; Delimpasi S; Pouli A; Vassilakopoulos TP; Michalis E; Giannouli S; Kartasis Z; Christoforidou A; Kokoviadou K; Hatzimichael E; Gika D; Megalakaki C; Papaioannou M; Kyrtsonis MC; Konstantopoulos K; Dimopoulos MA;
Eur J Haematol; 2017 Nov; 99(5):409-414. PubMed ID: 28675766
[TBL] [Abstract][Full Text] [Related]
47. Multiple myeloma: disease response assessment.
Zamagni E; Tacchetti P; Terragna C; Cavo M
Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
[TBL] [Abstract][Full Text] [Related]
48. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
49. Non-secretory myeloma: a clinician's guide.
Lonial S; Kaufman JL
Oncology (Williston Park); 2013 Sep; 27(9):924-8, 930. PubMed ID: 24282993
[TBL] [Abstract][Full Text] [Related]
50. Prognostic and predictive biomarker developments in multiple myeloma.
Wallington-Beddoe CT; Mynott RL
J Hematol Oncol; 2021 Sep; 14(1):151. PubMed ID: 34556161
[TBL] [Abstract][Full Text] [Related]
51. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
52. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
53. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
54. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma.
Sedlarikova L; Gromesova B; Kubaczkova V; Radova L; Filipova J; Jarkovsky J; Brozova L; Velichova R; Almasi M; Penka M; Bezdekova R; Stork M; Adam Z; Pour L; Krejci M; Kuglík P; Hajek R; Sevcikova S
Eur J Haematol; 2017 Sep; 99(3):223-233. PubMed ID: 28543758
[TBL] [Abstract][Full Text] [Related]
55. An update of the management of multiple myeloma: the changing landscape.
Reece DE
Hematology Am Soc Hematol Educ Program; 2005; ():353-9. PubMed ID: 16304403
[TBL] [Abstract][Full Text] [Related]
56. Evolving role of FDG PET/CT in multiple myeloma imaging and management.
Agarwal A; Chirindel A; Shah BA; Subramaniam RM
AJR Am J Roentgenol; 2013 Apr; 200(4):884-90. PubMed ID: 23521465
[TBL] [Abstract][Full Text] [Related]
57. New tools for diagnosis and monitoring of multiple myeloma.
San-Miguel JF; Paiva B; Gutiérrez NC
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714534
[TBL] [Abstract][Full Text] [Related]
58. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.
Szabo AG; Gang AO; Pedersen MØ; Poulsen TS; Klausen TW; Nørgaard P
Leuk Lymphoma; 2016 Nov; 57(11):2526-34. PubMed ID: 27243588
[TBL] [Abstract][Full Text] [Related]
60. [Classification and genetic abnormalities of multiple myeloma].
Hanamura I; Iida S
Nihon Rinsho; 2015 Jan; 73(1):17-27. PubMed ID: 25626298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
